Mannheim

• Study to allow access to dabrafenib and/or trametinib for subjects that are benefiting from dabrafenib and/or trametinib treatment in a Nova … Recruiting
  2023-509318-13-00 6 2018-01-15 Multiple indications
• Intracranial Injection of NK-92/​5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblast … Recruiting
  2024-511988-29-01 3 2017-11-08 Glioblastoma
• Prospective Randomized Open-label Trial to Evaluate risk faCTor management in patients with Unruptured intracranial aneurysms (PROTECT-U) Recruiting
  2024-517236-22-00 5 2017-09-20 Intradural saccular unruptured aneurysm
• SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependym … Recruiting
  2024-512222-28-00 10 2015-06-02 Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended recruitment
  2025-521067-13-00 5 2026-04-24 Atherosclerotic Cardiovascular Disease (ASCVD)
• A study in healthy people to compare how 2 different formulations of survodutide are taken up by the body Ended recruitment
  2025-522325-35-00 3 2025-10-27 Healthy volunteer trial
• Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer Ended recruitment
  2025-521115-40-00 4 2025-09-30 Advanced or Metastatic Non-small Cell Lung Cancer
• Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM) Ended recruitment
  2024-511452-40-00 10 2025-09-12 Oncology - Glioblastoma (GBM)
• A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Gen … Ended recruitment
  2024-513572-17-00 5 2025-08-20 Generalized Anxiety Disorder (GAD)
• First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Ended recruitment
  2023-506842-22-00 7 2025-05-19 Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513210-36-00 5 2025-04-04 Chronic Spontaneous Urticaria
• A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma Ended recruitment
  2024-513738-39-00 9 2025-03-18 IDH1-mutant Glioma
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 ( ISLEND- … Ended recruitment
  2024-514047-28-00 5 2025-01-27 HIV-1 Infection
• Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemother … Ended recruitment
  2024-511957-23-00 5 2025-01-03 Recurrent or Persistent Endometrial Cancer
• Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 W … Ended recruitment
  2023-505110-14-00 4 2024-12-02 Colorectal Cancer
• INCA34176-254: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ru … Ended recruitment
  2022-502168-19-00 4 2024-10-22 chronic graft-versus-host disease
• Frontline Asciminib combination in chronic phase CML Ended recruitment
  2024-516212-24-00 4 2024-10-08 Chronic Myeloid Leukemia
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended recruitment
  2023-506876-28-00 5 2024-08-01 The medical condition we are investigating is type 1 AMI (STEMI and NS
• A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei … Ended recruitment
  2023-508306-15-00 5 2024-06-26 Alzheimer’s Disease
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit … Ended recruitment
  2023-505928-59-00 5 2024-04-15 Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
• An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell pr … Ended recruitment
  2024-517959-12-00 9 2024-04-11 Relapsed/refractory B cell precursor acute lymphoblastic leukemia

Showing 169–192 of 361 trials